Sting crystals and modulators
US-2016210400-A1 · Jul 21, 2016 · US
Compositions and methods for cancer immunotherapy
US9770467B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9770467-B2 |
| Application number | US-201313912960-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 7, 2013 |
| Priority date | Jun 8, 2012 |
| Publication date | Sep 26, 2017 |
| Grant date | Sep 26, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (CDN)—that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, DC recruitment and proliferation, coupled with a potent DC activation stimulus.
First claim
Opening claim text (preview).
The invention claimed is: 1. A composition comprising: a cyclic purine dinucleotide which binds to STING and induces STING-dependent TBK1 activation; and an inactivated tumor cell which expresses and secretes granulocyte-macrophage colony-stimulating factor (GM-CSF). 2. A composition according to claim 1 , further comprising a pharmaceutically acceptable excipient. 3. A composition according to claim 1 , wherein the tumor cell is inactivated by treatment with radiation. 4. A composition according to claim 1 , wherein the cyclic purine dinuclotide is selected from the group consisting of c-di-AMP, c-di-GMP, c-di-IMP, c-AMP-GMP, c-AMP-IMP, and c-GMP-IMP, or combinations thereof. 5. A composition according to claim 1 , wherein the cyclic purine dinuclotide is formulated with one or more lipids. 6. A composition according to claim 5 , wherein the cyclic purine dinuclotide is formulated with digitonin. 7. A composition according to claim 5 , wherein the one or more lipids form a liposome. 8. A composition according to claim 1 , further comprising one or more adjuvants. 9. A composition according to claim 8 , wherein the one or more adjuvants comprise CpG and/or monophosphoryl lipid A.
Assignees
Inventors
Classifications
IL-12 · CPC title
Colony stimulating factors [CSF] · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9770467B2 cover?
- The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (CDN)—that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of…
- Who is the assignee on this patent?
- Univ Johns Hopkins, Aduro Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K35/13. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).